Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
Addendum, aggressive, aggressively, ahead, amicable, amidst, announced, Asian, Beach, Bluetooth, Boynton, BSM, bulk, Cardiology, cc, chance, costly, England, Fl, foothold, fruit, handled, hanging, jump, kick, lifting, lot, metropolitan, middleman, Ohio, opportunity, postpone, PPD, Quantum, ramped, reopened, respectfully, restart, rollout, save, sense, shelf, slimmed, stand, sutured, suturing, temporarily, underway, vary, week, Westlake, Westside
Removed:
automate, binomial, coincide, contingently, deadline, earliest, easy, Hedging, Iliad, infinity, instrument, Jan, Lake, lattice, LP, resultant, Salt, sequencing, split, Utah
Financial report summary
?Management Discussion
- Revenue in years ended July 31, 2020 and 2019 was $2,661,396 and $6,203,761, respectively. The decrease is due to the ceasing of NDS2 operations which generated $6,098,329 of revenue in the prior year, partially offset by increase in revenues from MediSource Pantheon and Olaregen of $2,193,006 and $450,288, respectively.
- Research and development expenses increased to $2,106,364 for the year ending July 31, 2020 compared to $1,748,882 in the prior fiscal year. The difference is primarily due to the $372,647 of expenses incurred by NGIO.
- The bad debt expense was $14,146 for the year ending July 31, 2020 compared to $3,252,439 in the prior fiscal year. The change was due to the impairment of accounts receivables and notes receivables derived from Veneto Holdings, LLC, which was written down in the 2019 fiscal year.